Grace Therapeutics GRCE
NASDAQ GRCE
$2.20 +0.06 (+2.80%)
At close: Aug 21, 2026 · 4:00 PM EDT

Grace Therapeutics (GRCE) Asset Utilization Ratio (2022)

Grace Therapeutics (GRCE) posted Asset Utilization Ratio of 0.0 for Q1 2022.

Grace Therapeutics (GRCE) Asset Utilization Ratio (2022) Analysis & Trends

Grace Therapeutics has reported Asset Utilization Ratio for 1 years, with the latest figure at 0.0 in Q1 2022.

  • Quarterly Asset Utilization Ratio changed N/A year-over-year to 0.0 in Q1 2022, while the trailing twelve-month figure through Mar 2022 was 0.0 (changed N/A YoY) and the FY2021 annual result came in at 0.0, changed N/A from the prior year.
  • Asset Utilization Ratio held at 0.0 in Q1 2022 per GRCE's latest filing.
  • Over five years, Asset Utilization Ratio peaked at 0.0 in Q1 2022 and troughed at 0.0 in Q1 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Asset Util. (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 0.47
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 0.38
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 0.20
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 0.69
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 0.90
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 0.13
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 0.54
9 Royalty Pharma 27.27 Bn 26.43 Bn - 0.13
10 Grace Therapeutics 37.99 Mn 37.99 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2022 0.00